Natunola Releases Q1 2010 Results

WINCHESTER, ON, May 11 /CNW Telbec/ - Natunola Health Biosciences Inc. (TSX-V:NHI) ("Natunola") reports that the revenue for the three months ended on March 31, 2010 was $386,523 as compared to $281,688 for the comparative period for 2009, which represented an increase of $104,835 or 37.2%. The increase in revenue is due to the increase in sales of the Company's personal care product lines. As a result, the Company had a lower net loss of $34,513 or -$0.00 per share for the three months ended March 31, 2010 as compared to a net loss of $130,605 or -$0.01 per share for the three months ended March 31, 2009.

The sales for the Company's personal care product lines increased by 200% or $154,859 for the three months ended March 31, 2010 versus the comparative period for 2009. The increase is a result of the Company's personal care product lines used by one of the world's top 10 cosmetic and personal care companies.

The sales for the Company's flax product lines decreased by 31.3% or $64,022 for the three months ended March 31, 2010 versus the comparative period for 2009. The decline is a result of fewer orders in Q1 2010.

    
    About the Company:
    ------------------
    

Natunola and its manufacturing plant are located in Winchester, Ontario. Natunola is a manufacturer and researcher in the field of flax seed derived omega -3 fatty acids, flax protein, flax lignans, specialty natural products, bio-nutrients and functional supplements for human and animal care markets. Natunola also produces canola oil gels and other natural ingredients for the cosmetic and personal care industry. Natunola has a retail health product line under the brand name of Natunola(R) health's delight. Natunola was the winner for the National Canadian Agri-Food Award of Excellence for Innovation for the year 2008.

Some of the statements contained in the release are forward-looking statements, such as estimates and statements that describe the Company's future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. Actual results in each case could differ materially from those currently anticipated in such statements.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.

%SEDAR: 00009761E

For further information: Dr. Nam Fong Han, President & CEO, Natunola Health Biosciences Inc., 661, St Lawrence Street, Winchester, Ontario, K0C 2K0, Tel [phone]